Clinical Trial Update: ENAC Blockade and Arterial Stiffness [Phase 2, Phase 3]

View source ↗

Summary

This update reports results from phase 2 and phase 3 trials evaluating ENAC blockade as a treatment strategy for overweight and obesity and insulin resistance, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Obesity

Drugs mentioned

• ENAC blockade investigational agent (epithelial sodium channel blocker)

Snippet

Sponsor: University of Missouri-Columbia | Conditions: Overweight and Obesity, Insulin Resistance | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-12-30